| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5813421 | Neuropharmacology | 2016 | 10 Pages |
Abstract
The present study shows that the potent anti-AIMs activity of NLX-112 is maintained upon repeated administration and supports the ongoing clinical development of NLX-112 as a novel antidyskinetic agent for PD patients receiving l-DOPA treatment.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Andrew C. McCreary, Mark A. Varney, Adrian Newman-Tancredi,